Oligodendroglioma pathophysiology: Difference between revisions
No edit summary |
|||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Oligodendroglioma}} | |||
{{CMG}}{{AE}}{{SR}} | {{CMG}}{{AE}}{{SR}} | ||
==Overview== | ==Overview== | ||
Oligodendroglioma arises from the tripotential [[glial cell|glial precursor cells]] and ''not'' from the bipotential [[oligodendrocyte]]s.<ref name=pathogenesis>General features of oligodendroglioma. Libre Pathology. http://librepathology.org/wiki/index.php/Oligodendroglioma#cite_note-1</ref> Genes associated with the pathogenesis of oligodendroglioma include :*[[translocation|t[1;19][q10;p10]]] (co-deletion of chromosomal arms [[chromosome 1|1p]] and [[chromosome 19|19q]]; most common) | |||
:*''[[mutation|NJDS]]'' | |||
:*''[[Isocitrate dehydrogenase|IDH1]]'' | |||
:*''[[IDH2]]'' | |||
:*''CIC'' | |||
:*''[[Far upstream element-binding protein 1|FUBP1]]'' | |||
:*''[[p53]]'' | |||
:*''[[CD57|Leu-7]]'' | |||
:*''[[TCF12|TCF-12]]'' | |||
:*''[[Ogt|MGMT]]'' | |||
:*''[[P73|TP73]]'' | |||
:*''[[EGFR]]'' | |||
:*''[[PTEN]]''<ref name=transloc>Molecular genetics of oligodendroglioma. https://en.wikipedia.org/wiki/Oligodendroglioma</ref><ref name="pmid21817013">{{cite journal| author=Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD, Hruban RH et al.| title=Mutations in CIC and FUBP1 contribute to human oligodendroglioma. | journal=Science | year= 2011 | volume= 333 | issue= 6048 | pages= 1453-5 | pmid=21817013 | doi=10.1126/science.1210557 | pmc=PMC3170506 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21817013 }} </ref><ref name=prog>Prognosis and treatment of oligodendroglioma. Wikipedia 2015. https://en.wikipedia.org/wiki/Oligodendroglioma</ref><ref name="pmid22072542">{{cite journal| author=Yip S, Butterfield YS, Morozova O, Chittaranjan S, Blough MD, An J et al.| title=Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. | journal=J Pathol | year= 2012 | volume= 226 | issue= 1 | pages= 7-16 | pmid=22072542 | doi=10.1002/path.2995 | pmc=PMC3246739 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22072542 }} </ref><ref name="pmid26068201">{{cite journal| author=Labreche K, Simeonova I, Kamoun A, Gleize V, Chubb D, Letouzé E et al.| title=TCF12 is mutated in anaplastic oligodendroglioma. | journal=Nat Commun | year= 2015 | volume= 6 | issue= | pages= 7207 | pmid=26068201 | doi=10.1038/ncomms8207 | pmc=PMC4490400 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26068201 }} </ref><ref name="pmid21937591">{{cite journal| author=Suri V, Jha P, Agarwal S, Pathak P, Sharma MC, Sharma V et al.| title=Molecular profile of oligodendrogliomas in young patients. | journal=Neuro Oncol | year= 2011 | volume= 13 | issue= 10 | pages= 1099-106 | pmid=21937591 | doi=10.1093/neuonc/nor146 | pmc=PMC3177666 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21937591 }} </ref><ref name="pmid9038605">{{cite journal| author=Hagel C, Laking G, Laas R, Scheil S, Jung R, Milde-Langosch K et al.| title=Demonstration of p53 protein and TP53 gene mutations in oligodendrogliomas. | journal=Eur J Cancer | year= 1996 | volume= 32A | issue= 13 | pages= 2242-8 | pmid=9038605 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9038605 }} </ref><ref name="pmiddoi:10.1016/S0090-3019(03)00167-8">{{cite journal| author=Schmoldt A, Benthe HF, Haberland G| title=Digitoxin metabolism by rat liver microsomes. | journal=Biochem Pharmacol | year= 1975 | volume= 24 | issue= 17 | pages= 1639-41 | pmid=doi:10.1016/S0090-3019(03)00167-8 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10 }} </ref><ref name="von DeimlingHartmann2005">{{cite journal|last1=von Deimling|first1=A|last2=Hartmann|first2=C|title=Oligodendrogliomas: Impact of molecular genetics on treatment|journal=Neurology India|volume=53|issue=2|year=2005|pages=140|issn=0028-3886|doi=10.4103/0028-3886.16394}}</ref> | |||
==Pathophysiology== | ==Pathophysiology== | ||
===Pathogenesis=== | ===Pathogenesis=== |
Revision as of 14:07, 14 October 2015
Oligodendroglioma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Oligodendroglioma pathophysiology On the Web |
American Roentgen Ray Society Images of Oligodendroglioma pathophysiology |
Risk calculators and risk factors for Oligodendroglioma pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
Oligodendroglioma arises from the tripotential glial precursor cells and not from the bipotential oligodendrocytes.[1] Genes associated with the pathogenesis of oligodendroglioma include :*t[1;19][q10;p10] (co-deletion of chromosomal arms 1p and 19q; most common)
Pathophysiology
Pathogenesis
- Oligodendroglioma does not arise from the bipotential oligodendrocytes, although tumor cells look very similiar.[1]
- Oligodendroglioma arises from the tripotential glial precursor cells.
Genetics
- Development of oligodendroglioma is the result from multiple genetic mutations.
- Genes associated with the pathogenesis of oligodendroglioma include:[2][3][4][5][6][7][8][9][10]
- There is a strong association of oligodendroglioma with expression of receptor tyrosine kinases that activate PI3K/AKT, RAS/MAP, and PLC/PKC pathways.[10]
Gross Pathology
- On gross pathology, oligodendroglioma is characterized by a well-circumscribed, gelatinous, gray mass which may expand a gyrus and remodel the skull.[11]
- Other characteristic gross pathological features associated with oligodendroglioma include:[11][10]
- Calcification (70-90%; one of the most frequently calcifying tumors)
- Focal hemorrhage
- Cystic (20%)
- Common intracranial sites associated with oligodendroglioma include:[12]
- Cerebral hemispheres - distribution between frontal, parietal, temporal, and occipital lobe approximates 3:2:2:1
- Posterior fossa (rare)
- Intramedullary spinal cord (very rare)
Images
-
Brain: Oligodendroglioma: Gross; natural color, large, well circumscribed lesion in left frontal lobe
Microscopic Pathology
On microscopic histopathological analysis, oligodendroglioma is characterized by:[10] [13][14][15]
- Diffusely growing tumor
- Highly cellular lesion composed of cells resembling fried eggs with:
- Round nucleus - key feature
- Distinct cell borders
- Moderate-to-marked nuclear atypia with speckled "salt-and-pepper" chromatin pattern
- Clear cytoplasm
- Some oligodendrogliomas have eosinophilic cytoplasm with focal perinuclear clearing
- Acutely branched capillary sized vessels - "chicken-wire" like appearance
- Abundant, delicate appearing; may vaguely resemble a paraganglioma at low power
- Calcifications - striking feature
- Perifocal edema - rare
- Few tumors may exhibit eosinophilic granular bodies
- Some tumors may show a spongioblastoma-like growth pattern
On microscopic histopathological analysis, anaplastic oligodendroglioma is characterized by:[13]
- Focal or diffusely increased cell density
- Atypical to frankly pleomorphic cells or multinucleated giant cells
- Tumor cells may be plasmacytoid (i.e. have a plasma cell-like appearance)
- Also called as minigemistocytes
- Significant or brisk mitotic activity (>= 6 mitoses per 10 HPF)
- Necrosis
- Apoptotic cells
- Microvacular proliferation
- Either in the form of 'glomeruloid' vessels or endothelial hyperplasia
Gallery
-
Oligodendroglioma low magnification showing the characteristic small, branching, chicken wire-like blood vessels.H&E stain.[16]
-
Oligodendroglioma high magnification showing highly cellular lesion composed of cells resembling fried eggs with distinct cell borders moderate-to-marked nuclear atypia, and a clear cytoplasm. Acutely branched capillary sized vessels - "chicken-wire" like appearance.[16]
-
Low power magnification of oligodendroglioma biopsy specimen showing discrete infiltration of the surrounding brain (HE stain, x40 mag).[17]
-
Histopathology of anaplastic oligodendroglioma showing minigemistocytes and mitoses among tumor cells with perinuclear halo. HE stain.[17]
-
Histopathology of anaplastic oligodendroglioma (MAP2 staining) showing perinuclear immunoreactivity of tumor cells.[17]
-
Histopathology of anaplastic oligodendroglioma (IDH1-R132H staining) showing immunoreactivity of tumor cells indicating presence of the isocitrate dehydrogenase 1-R132H mutation.[17]
Immunohistochemistry
Oligodendroglioma is demonstrated by positivity to tumor markers such as:[18][19][10]
- MAP2
- GFAP
- S-100
- EMA
- IDH1-R132H
- ATRX
- Ki-67
- NSE
- Synaptophysin
- OLIG1
- OLIG2
References
- ↑ 1.0 1.1 General features of oligodendroglioma. Libre Pathology. http://librepathology.org/wiki/index.php/Oligodendroglioma#cite_note-1
- ↑ 2.0 2.1 Molecular genetics of oligodendroglioma. https://en.wikipedia.org/wiki/Oligodendroglioma
- ↑ 3.0 3.1 Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD, Hruban RH; et al. (2011). "Mutations in CIC and FUBP1 contribute to human oligodendroglioma". Science. 333 (6048): 1453–5. doi:10.1126/science.1210557. PMC 3170506. PMID 21817013.
- ↑ 4.0 4.1 Prognosis and treatment of oligodendroglioma. Wikipedia 2015. https://en.wikipedia.org/wiki/Oligodendroglioma
- ↑ 5.0 5.1 Yip S, Butterfield YS, Morozova O, Chittaranjan S, Blough MD, An J; et al. (2012). "Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers". J Pathol. 226 (1): 7–16. doi:10.1002/path.2995. PMC 3246739. PMID 22072542.
- ↑ 6.0 6.1 Labreche K, Simeonova I, Kamoun A, Gleize V, Chubb D, Letouzé E; et al. (2015). "TCF12 is mutated in anaplastic oligodendroglioma". Nat Commun. 6: 7207. doi:10.1038/ncomms8207. PMC 4490400. PMID 26068201.
- ↑ 7.0 7.1 Suri V, Jha P, Agarwal S, Pathak P, Sharma MC, Sharma V; et al. (2011). "Molecular profile of oligodendrogliomas in young patients". Neuro Oncol. 13 (10): 1099–106. doi:10.1093/neuonc/nor146. PMC 3177666. PMID 21937591.
- ↑ 8.0 8.1 Hagel C, Laking G, Laas R, Scheil S, Jung R, Milde-Langosch K; et al. (1996). "Demonstration of p53 protein and TP53 gene mutations in oligodendrogliomas". Eur J Cancer. 32A (13): 2242–8. PMID 9038605.
- ↑ 9.0 9.1 Schmoldt A, Benthe HF, Haberland G (1975). "Digitoxin metabolism by rat liver microsomes". Biochem Pharmacol. 24 (17): 1639–41. PMID doi:10.1016/S0090-3019(03)00167-8 Check
|pmid=
value (help). - ↑ 10.0 10.1 10.2 10.3 10.4 10.5 von Deimling, A; Hartmann, C (2005). "Oligodendrogliomas: Impact of molecular genetics on treatment". Neurology India. 53 (2): 140. doi:10.4103/0028-3886.16394. ISSN 0028-3886.
- ↑ 11.0 11.1 Gross appearance of oligodendroglioma. Dr Henry Knipe and Dr Frank Gaillard et al. http://radiopaedia.org/articles/oligodendroglioma
- ↑ Gross/radiologic findings of oligodendroglioma. Libre Pathology. http://librepathology.org/wiki/index.php/Oligodendroglioma
- ↑ 13.0 13.1 Microscopic features of oligodendroglioma. Libre Pathology. http://librepathology.org/wiki/index.php/Oligodendroglioma
- ↑ Ersen, Ayca (2008), Pathology of malignant gliomas: Challenges of everyday practice and the WHO 2007, Turkish Journal of Pathology, retrieved 9 October, 2015 Check date values in:
|accessdate=
(help) - ↑ Eskandar EN, Loeffler JS, O'Neill AM, Hunter GJ, Louis DN (2004). "Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 33-2004. A 34-year-old man with a seizure and a frontal-lobe brain lesion". N Engl J Med. 351 (18): 1875–82. doi:10.1056/NEJMcpc049025. PMID 15509821.
- ↑ 16.0 16.1 Images of microscopic appearance of oligodendroglioma. Wikipedia 2015. https://en.wikipedia.org/wiki/Oligodendroglioma
- ↑ 17.0 17.1 17.2 17.3 Images of oligodendroglioma. Libre Pathology 2015. http://librepathology.org/wiki/index.php/Oligodendroglioma
- ↑ IHC of oligodendroglioma. Libre Pathology. http://librepathology.org/wiki/index.php/Oligodendroglioma
- ↑ Hilbig A, Barbosa-Coutinho LM, Netto GC, Bleil CB, Toscani NV (2006). "[Immunohistochemistry in oligodendrogliomas]". Arq Neuropsiquiatr. 64 (1): 67–71. doi:/S0004-282X2006000100014 Check
|doi=
value (help). PMID 16622556.